Switching Biological Therapies in Severe Asthma
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24119563 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Giulia Scioscia und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Foggia, 71121 Foggia, Italy. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Currently, three classes of monoclonal antibodies targeting type 2 inflammation pathways are available in Italy for the treatment of severe asthma: anti-IgE (Omalizumab), anti-IL-5/anti-IL-5Rα (Mepolizumab and Benralizumab), and anti-IL-4Rα (Dupilumab). Numerous randomized controlled trials (RCTs) and real-life studies have been conducted to define their efficacy and identify baseline patients’ characteristics potentially predictive of favorable outcomes. Switching to another monoclonal antibody is recommended in case of a lack of benefits. The aim of this work is to review the current knowledge on the impact of switching biological therapies in severe asthma as well as on predictors of treatment response or failure. Almost all of the information about switching from a previous monoclonal antibody to another comes from a real-life setting. In the available studies, the most frequent initial biologic was Omalizumab and patients who were switched because of suboptimal control with a previous biologic therapy were more likely to have a higher baseline blood eosinophil count and exacerbation rate despite OCS dependence. The choice of the most suitable treatment may be guided by the patient’s clinical history, biomarkers of endotype (mainly blood eosinophils and FeNO), and comorbidities (especially nasal polyposis). Due to overlapping eligibility, larger investigations characterizing the clinical profile of patients benefiting from switching to different monoclonal antibodies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, University of Foggia, 71121 Foggia, Italy.
- Department of Clinical and Experimental Medicine, University of Catania, 95124 Catania, Italy.
- Respiratory Medicine Unit, Policlinico "G. Rodolico-San Marco", 95123 Catania, Italy.
- Institute of Respiratory Diseases, Policlinico Foggia, 71121 Foggia, Italy.
- Department of Medical and Surgical Sciences, Digestive Disease Center, Fondazione Policlinico A. Gemelli IRCCS, 00168 Rome, Italy.
- Department of Health Sciences, University "Magna Graecia" of Catanzaro, 88100 Catanzaro, Italy.
ORCID-Profile: Giulia Scioscia, Santi Nolasco, Raffaele Campisi, Carla Maria Irene Quarato, Cristiano Caruso, Corrado Pelaia, Andrea Portacci, Claudia Crimi
Zitieren
APA
Scioscia, G., Nolasco, S., Campisi, R., Quarato, C. M. I., Caruso, C., Pelaia, C., Portacci, A., & Crimi, C. (2023). Switching Biological Therapies in Severe Asthma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24119563
Vancouver
Scioscia G, Nolasco S, Campisi R, Quarato CMI, Caruso C, Pelaia C, et al. Switching Biological Therapies in Severe Asthma. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24119563
BibTeX
@article{Scioscia2023,
author = {Scioscia, Giulia and Nolasco, Santi and Campisi, Raffaele and Quarato, Carla Maria Irene and Caruso, Cristiano and Pelaia, Corrado and Portacci, Andrea and Crimi, Claudia},
title = {Switching Biological Therapies in Severe Asthma},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24119563}
}
EUVIMED